Up to October 2016, 3843 participants were analyzed. The incidence rates showed a notable difference between the infliximab cohort (47·8 per 1000 person-years) [95% confidence interval (CI) 35·7-64·0] and the nonbiologic systemic cohort, which reported 14·2 per 1000 person-years (95% CI 11·5-17·4). Infliximab use correlated with an overall heightened risk of serious infection compared to both nonbiologic treatments [adjusted HR (adjHR) 1·95, 95% CI 1·01-3·75] and exclusive methotrexate use (adjHR 2·96, 95% CI 1·58-5·57). Particularly within the initial 6 months of therapy, infliximab exhibited a notably higher risk of serious infection (adjHR 3·49, 95% CI 1·14-10·70).

Citation: Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2019 Feb;180(2):329-337. doi: 10.1111/bjd.17036. Epub 2018 Oct 21. Erratum in: Br J Dermatol. 2019 Sep;181(3):646. PMID: 30070708; PMCID: PMC7379582.